Trial reportAnnals of medicine2022
The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for
Trial report in Annals of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Vonoprazan-amoxicillin dual therapy vs. proton pump inhibitor based dual therapy forFrontiers in medicine · 2025Pooled it
- High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment ofSaudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- Susceptibility-Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial.MicrobiologyOpen · 2026Trial
- Vonoprazan versus rabeprazole in dual therapy with amoxicillin for Helicobacter pylori eradication: a prospective, multicenter, open-label, randomized controlled trial.BMC infectious diseases · 2026Trial
- Vonoprazan-based dual therapy with amoxicillin or doxycycline versus bismuth-containing quadruple therapy forFrontiers in cellular and infection microbiology · 2026Trial
- Evolution of Amoxicillin-Based Mono-Antibiotic Regimens forMicroorganisms · 2026Review
- Safety of high-dose dual therapy forFrontiers in pharmacology · 2026Article
- Novel non-antibiotic triple therapy forFrontiers in medicine · 2026Article
- Helicobacter pylori infection increases the risk of dyslipidemia in Chinese non-obese and non-diabetic population from the perspective of age category: a retrospective cross-sectional study.BMC infectious diseases · 2025Article
- Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan forMicroorganisms · 2025Review
- Article
- Article
- Ten-day vonoprazan-amoxicillin dual therapy versus 14-day esomeprazole-amoxicillin dual therapy for first-lineTherapeutic advances in gastroenterology · 2024Article
- High-dose dual therapyTherapeutic advances in gastroenterology · 2023Article
- 14-day pantoprazole- and amoxicillin-containing high-dose dual therapy forFrontiers in pharmacology · 2023Article
- Sport Resource Classification Algorithm for Health Promotion Based on Cloud Computing: Rhythmic Gymnastics' Example.Journal of environmental and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the safety and efficacy of high-dose amoxicillin-proton pump inhibitor dual therapy, and to provide a new eradication regimen as a first-line option for patients with
methodsA total of 971
resultsThere were no statistical differences in age, gender, the total clinical symptom scores before and after initial treatment, the compliance, and the degree of remission of symptoms before and after initial treatment between the two groups. The eradication rates of
conclusionsFor the initial treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.